The global diagnostic nuclear medicines market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Nuclear medicine uses small amounts of radioactive material called radiotracers, which are used to evaluate, diagnose, and treat various diseases. As far as their applications are concerned, diagnostic nuclear medicines hold quite promising opportunities in the field of oncology, and cardiology, among others. This is anticipated to be the major driving factor for market growth. Other key factors that can be attributed to the market growth include the rising prevalence and incidence of various chronic conditions such as cancer and cardiac ailments.
To Request a Sample of our Report on Global Diagnostic Nuclear Medicines Market: https://www.omrglobal.com/request-sample/diagnostic-nuclear-medicines-market
There have been recorded a substantial number of mortalities due to cancer and CVDs which made it even more critical to look out for early diagnostics and treatment solutions such as diagnostic nuclear medicines. As per the WHO, in 2020, cancer was the leading cause of mortalities globally, accounting for nearly 10 million mortalities. It is further estimated that 19.3 million new yearly cancer cases are projected to be reported globally by 2025. According to the WHO, globally, 17.9 million individuals died from CVDs in 2019, accounting for 32% of the overall mortalities. This figure is expected to reach 23.3 million by 2030. Thus, nuclear medicine’s role in disease diagnosis and treatment can present opportunities for market growth during the forecast period.
Some key players operating in the market include Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in 2021, Bracco entered into a partnership with CardioNavix which is aimed at improving patients’ approaches to cardiac PET imaging.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG.
A full Report of Global Diagnostic Nuclear Medicines Market is Available @ https://www.omrglobal.com/industry-reports/diagnostic-nuclear-medicines-market
Global Diagnostic Nuclear Medicines Market Report Segmentation
By Application
- Cardiology,
- Bone scans,
- Thyroid,
- Pulmonary scans,
- Others
Global Diagnostic Nuclear Medicines Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/diagnostic-nuclear-medicines-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
